THE COLORECTAL CANCER: EPIDEMIOLOGICAL, CLINICAL, THERAPEUTIC AND MOLECULAR PROFIL
Session type: Poster / e-Poster / Silent Theatre session
Theme: Diagnosis and therapy
Colorectal cancer represents a major public health problem in Algeria, it is the 2nd cancer in men and in women, with increased gradually, over the past decade, the therapeutic arsenal for this indication has been enriched by new molecules including anti epidermal growth factor receptor namely cetuximab. The studies have demonstrated the efficiency of the anti-EGFR in metastatic cancers. Patients are mutated KRAS do not responds to these treatments.The aim of our study was to analyse the clinic, epidemiological, therapeutic and molecular characteristics of colorectal cancer.
This retrospective study in our department of radiotherapy oncology of Blida was conducted on thirty patients suffering from colorectal cancer
Thirty patients had metastatic colorectal cancer, 24 men and 6 women, the median age was 56 (32-79years), we identified 60% of colon cancer and 40% of rectal cancer. The clinical symptoms was dominated by rectal bleeding, the adenocarcinoma was the most common histological type 93%. KRAS wild type was found positive in 20 patients. Tumors classified as T3 and T4 represent 95% of cases, chemotherapy with target therapy was indicated in all patients, 75% of patients were metastatic at diagnosis, curative surgical treatment was found in 7 patients
Colorectal cancer remains a leading cause of cancer death. A considerable proportion of cancers are diagnosed at an advanced stage. A delay in diagnosis is the main reason for poor prognosis. Cetuximab have demonstrated efficacy in the treatment of metastatic colorectal cancers